Table 2. The association between PD-L1 expression and EGFR-TKIS' efficacy in univariate and multivariate logistic regression analysis#.
| Parameter | ORR | DCR | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Univariate analysis | Multivariate analysis | Univariate analysis | Multivariate analysis | |||||||||||||||
| PR | SD+PD | OR | 95%CI | P-value | OR | 95%CI | P-value | PD | PR+SD | OR | 95%CI | P-value | OR | 95%CI | P-value | |||
| Age | ||||||||||||||||||
| ≤50 | 9 | 36 | 0.758 | 0.329-1.748 | 0.516 | 0.663 | 0.264-1.666 | 0.382 | 10 | 35 | 0.707 | 0.304-1.645 | 0.421 | 0.495 | 0.181-1.358 | 0.172 | ||
| >50 | 1 | 31 | 94 | 1 | 21 | 104 | ||||||||||||
| Gender | ||||||||||||||||||
| female | 21 | 56 | 1.461 | 0.717-2.974 | 0.296 | 0.541 | 0.220-1.331 | 0.181 | 7 | 70 | 3.478 | 1.407-8.600 | 0.007 | 1.899 | 0.528-6.837 | 0.326 | ||
| male | 1 | 19 | 74 | 1 | 24 | 69 | ||||||||||||
| Smoking | ||||||||||||||||||
| no | 35 | 78 | 4.667 | 1.716-12.693 | 0.003 | 5.776 | 1.763-18.863 | 0.004 | 13 | 100 | 3.55 | 1.589-7.930 | 0.002 | 1.942 | 0.612-6.154 | 0.260 | ||
| yes | 1 | 5 | 52 | 1 | 18 | 39 | ||||||||||||
| Pathology | ||||||||||||||||||
| ADC | 38 | 107 | 4.084 | 0.919-18.150 | 0.064 | 3.834 | 0.793-18.538 | 0.095 | 24 | 121 | 1.961 | 0.738-5.207 | 0.177 | 1.348 | 0.439-4.142 | 0.602 | ||
| non-ADC | 1 | 2 | 23 | 1 | 7 | 18 | ||||||||||||
| Stage | ||||||||||||||||||
| IIIB | 1 | 8 | 0.391 | 0.047-3.225 | 0.383 | 0.206 | 0.023-1.877 | 0.161 | 1 | 8 | 1.832 | 0.221-15.208 | 0.575 | 0.576 | 0.046-7.175 | 0.668 | ||
| IV | 1 | 39 | 122 | 1 | 30 | 131 | ||||||||||||
| EGFR | ||||||||||||||||||
| wild type | 8 | 63 | 0.266 | 0.114-0.621 | 0.002 | 0.351 | 0.137-0.904 | 0.030 | 26 | 42 | 0.092 | 0.033-0.256 | <0.001 | 0.113 | 0.038-0.342 | <0.001 | ||
| mutation | 1 | 32 | 67 | 1 | 5 | 97 | ||||||||||||
| EGFR-TKI | ||||||||||||||||||
| 1st line | 24 | 59 | 1.805 | 0.878-3.711 | 0.108 | 1.863 | 0.798-4.349 | 0.150 | 10 | 73 | 2.323 | 1.020-5.291 | 0.045 | 1.394 | 0.525-3.702 | 0.506 | ||
| ≥2nd line | 1 | 16 | 71 | 1 | 21 | 66 | ||||||||||||
| PD-L1 | ||||||||||||||||||
| negative | 15 | 43 | 1.214 | 0.581-2.537 | 0.606 | 1.674 | 0.711-3.939 | 0.238 | 12 | 46 | 0.783 | 0.350-1.751 | 0.551 | 1.109 | 0.445-2.764 | 0.824 | ||
| positive | 1 | 25 | 87 | 1 | 19 | 93 | ||||||||||||
| EGFR wild-type subgroup | ||||||||||||||||||
| PD-L1 negative | 3 | 26 | 0.854 | 0.187-3.891 | 0.838 | 10 | 19 | 1.169 | 0.436-3.137 | 0.756 | ||||||||
| PD-L1 positive | 1 | 5 | 37 | 1 | 16 | 26 | ||||||||||||
| EGFR mutant subgroup | ||||||||||||||||||
| PD-L1 negative | 12 | 17 | 1.765 | 0.715-4.353 | 0.218 | 2 | 27 | 0.604 | 0.096-3.822 | 0.593 | ||||||||
| PD-L1 positive | 1 | 20 | 50 | 1 | 3 | 67 | ||||||||||||
#
A total of 170 non-small cell lung cancer patients were included.
Abbreviations: ORR, objective response rate; DCR, disease control rate; PR, partial response; SD, stable disease; PD, progressive disease ; OR, odd ratio; 95%CI, 95% confidence intervals; ADC, adenocarcinoma; non-ADC, non-adenocarcinoma; EGFR, epidermal growth factor receptor; EGFR-TKI, EGFR-tyrosine kinase inhibitor; PD-L1, programmed cell death-ligand 1.